Research - Ann Arbor, Michigan, United States
Gema is developing noninvasive human oocyte and embryo selection methods to fundamentally improve the clinical outcomes of in vitro fertilization (IVF).Our technology originates from work conducted at the Michigan State University Cellular Reprogramming Laboratory, the Yale University School of Medicine, and the University of Oxford Institute of Reproductive Sciences under the leadership of Dr. Jose Cibelli and Dr. Dagan Wells, two of the world's leading scientists in reproductive technologies.Gema works extensively with some of the the top clinics in the world: Oxford, Yale School of Medicine, Cleveland Clinic Fertility Center, University of Iowa Hospitals and Clinics, Reproductive Medicine Instititute (Chicago), Pacific Fertility Center (San Francisco), Jarrett Fertility Group (Indianapolis), Technobios Procreazione (Italy), and Clinic de las Condes (Chile).
Gmail
Google Apps